Full Breakdown
Lenacapavir Rollout in Eswatini: A Critical Response to HIV Epidemic Amid Aid Cuts
3/25/2026, 9:16:40 AM
Introduction to the HIV Crisis in Eswatini
Eswatini, once labeled the epicenter of the HIV epidemic, continues to grapple with some of the highest infection rates globally. The kingdom has seen significant progress in reducing new infections from a peak of 21,000 annually two decades ago to 4,000 in 2023. However, the ongoing challenges are starkly illustrated by individuals like Lianne, a 24-year-old who turned to sex work after losing her parents to AIDS. With limited access to HIV preventative medication, Lianne's situation underscores the urgent need for effective interventions.
The Promise of Lenacapavir
Lenacapavir, a new long-acting HIV prevention drug developed by Gilead Sciences, is being hailed as a potential game-changer in the fight against HIV. This twice-yearly injection is being rolled out in nine high-risk countries, including Eswatini, with the aim of protecting millions and possibly ending the AIDS epidemic. The United Nations has described lenacapavir as “the closest thing we have to a vaccine,” and the Global Fund to Fight AIDS, Tuberculosis and Malaria plans to deliver it to two million people by 2028.
Impact of Foreign Aid Cuts
The rollout of lenacapavir comes in the wake of significant cuts to foreign aid, particularly from the United States and the United Kingdom, which previously funded nearly half of Eswatini's HIV response. These cuts have resulted in the closure of mobile clinics that provided essential services, leaving many, including vulnerable populations like sex workers, without access to life-saving medications. David Maseko from HealthPlus for Men highlights the dire consequences of these aid reductions, noting a surge in individuals off their HIV medication and a lack of community testing.
Criticism of the Current Rollout Strategy
Despite the optimism surrounding lenacapavir, experts express concern that the current rollout is insufficient to meet global needs. UNAIDS estimates that 20 million people require access to PrEP in the coming years, while the two million targeted by the Global Fund represents less than 10% of that goal. Dr. Diojki Bahati from Médecins Sans Frontières emphasizes the necessity for a comprehensive global strategy, warning that piecemeal solutions will not effectively address the epidemic.
Official Statements and Responses
Dianne Stewart from the Global Fund remarked, “This has been a defining moment for the AIDS epidemic,” emphasizing the importance of equitable access to new tools. However, she also cautioned that without proper investment and support, the impact of lenacapavir could be limited. Carmen Pérez Casas from Unitaid warned that the rising number of new infections could lead to significant long-term costs, estimating an additional $52 million per year for treatment if infections continue to rise.
Verbatim Quotes
- “This is lifesaving for us,” — Arianna, 17, a teenage sex worker receiving lenacapavir.
- “If they are cutting the funding, it means we will be exposed and die of HIV. Please help.” — Lianne, 24, HIV-positive sex worker.
Conclusion: The Path Forward
As Eswatini embarks on the lenacapavir rollout, the demand for this innovative treatment is evident. However, the success of this initiative hinges on global cooperation and sustained funding. Without a comprehensive approach to HIV prevention and treatment, the progress made could be jeopardized, leaving vulnerable populations at risk. The call for continued support from international donors remains critical in the fight against HIV/AIDS.
